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27620
Effects of ruxolitinib cream in patients with atopic dermatitis
with baseline body surface area $10% and Eczema Area and
Severity Index score $16: Pooled results from two phase 3
studies
Eric L. Simpson, MD, MCR, Oregon Health & Science University; Leon Kircik,
MD, Icahn School of Medicine at Mount Sinai; Andrew Blauvelt, MD, MBA,
Oregon Medical Research Center; Michael E. Kuligowski, MD, PhD, MBA, Incyte
Corporation; May E. Venturanza, MD, Incyte Corporation; Kang Sun, PhD, Incyte
Corporation; Lawrence F. Eichenfield, MD, University of California San Diego
Atopic dermatitis (AD), a highly pruritic inflammatory skin disease, is often stratified
using objective (Investigator’s Global Assessment [IGA], Eczema Area and Severity
Index [EASI], body surface area [BSA]) and subjective (eg, itch numerical rating scale
[NRS]) assessment tools. Efficacy and safety of ruxolitinib cream, a Janus kinase
(JAK) 1/JAK2 inhibitor, was investigated in two phase 3 randomized studies (TRuEAD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) that enrolled patients aged $12
years with AD for $2 years, an IGA score of 2 or 3, and 3%e20% affected BSA. In
total, 1249 patients (both studies combined) were enrolled; median age was 32
years. Patients were randomized (2:2:1) to 0.75% ruxolitinib, 1.5% ruxolitinib, or
vehicle cream (all twice daily) for 8 weeks of double-blinded treatment. Here we
report the efficacy of ruxolitinib using pooled data from these studies in a
subpopulation of patients with BSA $10% and EASI $16 at baseline (n ¼ 81). In
these patients, higher response rates were observed with ruxolitinib (0.75%/1.5%)
vs vehicle for IGA-treatment success ([score of 0 or 1 with $2-grade improvement
from baseline]; 50.0%/59.4% vs 0%), $75% improvement in EASI from baseline
(75.0%/71.9% vs 7.7%), and a $4-point reduction in itch NRS score (50.0%/61.1% vs
27.3%). In summary, this subset of patients with AD (eligible for both topical and
systemic therapies) showed high rates of clinical response with ruxolitinib cream. In
patients such as those described here, ruxolitinib cream may be efficacious, delaying
or avoiding the use of systemic therapy.
Commercial Disclosure: This study was funded by Incyte Corporation.

27629
Malignancy rates through 4 years of follow-up in guselkumabtreated moderate to severe psoriasis patients from the VOYAGE 1
and 2 trials and comparisons to the general United States
population
Kim A. Papp, MD, PhD, K Papp Clinical Research and Probity Medical Research
Inc; Kristian Reich, MD, Translational Research in Inflammatory Skin Diseases,
Institute for Health Services Research in Dermatology and Nursing, University
Medical Center Hamburg-Eppendorf; Kenneth B. Gordon, MD, Medical College of
Wisconsin; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai; Michael
Song, Janssen Research & Development, LLC; Megan Miller, Janssen Research &
Development, LLC; Paraneedharan Ramachandran, Janssen Research &
Development, LLC; Yaung-Kaung Shen, Janssen Research & Development, LLC;
Connie B. Lin, Janssen Research & Development, LLC; Andrew Blauvelt, MD,
MBA, Oregon Medical Research Center
Objective: To summarize the incidence of malignancies by NMSC and malignancies
other than NMSC/cervical cancer in situ, using pooled VOYAGE1&2 data through 4years of guselkumab (GUS) treatment; results were compared with expected rates in
the general USpopulation.
Methods: Rates of malignancies were evaluated cumulatively through 4-years in
3groups: GUS (GUS,PBO/GUS), adalimumab (ADA)/GUS, and Combined GUS
(GUS,ADA/GUS). Cumulative rates/100PY of follow-up, and by-year of exposure
through Yr1, fromYr1-Yr2, from Yr2-Yr3, and from Yr3-Yr4 were evaluated.
Standardized incidence ratios (SIR; 95%CI) of malignancies other than
NMSC/cervical cancer in situ reported in GUS-treated patients were compared
with rates expected in the general US population derived from the SEER database
(2000-2015). Postmarketing data were also evaluated.
Results: 1,721 patients were treated with GUS (medianPY of follow-up:3.6) through
4-years; 21 had NMSC and 26 had a malignancy other than NMSC. Rates/100PY (95%
CI) of NMSC were: GUS 0.34 (0.19,0.57); ADA/GUS 0.50 (0.20,1.03); and
Combined GUS 0.38 (0.23,0.58). Rates for other malignancies were: GUS 0.53
(0.33,0.80); ADA/GUS 0.28 (0.08,0.72); and Combined GUS 0.47 (0.31,0.69). Over
time, there was year-to-year variability, but no increasing trend was evident. Rates of
malignancies (other than NMSC/cervical cancer in situ) through 4-years of GUS
exposure were generally consistent with those from the general US population
(Combined GUS SIR [95%CI]: 0.98 [0.64,1.43]). Most commonly reported malignancies (n; SIR [95%CI]) were: breast cancer (n ¼ 5; 1.61 [0.52,3.75]), melanoma (n
¼ 4; 1.79 [0.49,4.59]), and prostate cancer (n ¼ 4; 0.78 [0.21,1.99]). Reporting rates
of malignancy/100PY in postmarketing surveillance (81,502 PY), since first drug
approval in 2017, were 0.02 for NMSC and 0.25 for other than NMSC, without
identification of new safety signals for malignancies.
Conclusions: Through 4-years of GUS treatment in VOYAGE1&2, overall incidence
rates of malignancy were low and generally consistent with those expected in the
general US population.
Commercial Disclosure: 100% is sponsored by Janssen Research & Development,
LLC.

27624
U.S. academic dermatologists’ attitudes and perceptions toward
chaperone use during genital examinations
Jalal Maghfour, MD, Tulane University School of Medicine; Lauren
Chen, MS, Tulane University School of Medicine; Justin Olson, BS,
Tulane University School of Medicine; Catherine Roach, MD, Department of
Dermatology, Tulane University School of Medicine; Andrea Murina, MD,
Department of Dermatology, Tulane University School of Medicine
Chaperones play a central role in enhancing patient care and assure the safety of
both patient and provider. Yet, chaperone use varies among physicians. We aim to
explore dermatologists’ viewpoint on chaperone use and determine frequency of
genital examination in practice.
Methods: A 12-item questionnaire was distributed to 500 academic dermatologists
using the Association of Professors of Dermatology and Medical Dermatology
Society listserv. Data were collected from January to May 2020.
Results: 80 respondents completed the questionnaire (mean [SD]; age 47.8[12.7]
years; 45 females [55.6%]; clinical experience 17[13.3] years; response rate 16%).
8.8% of participants ‘never or very rarely’ examine female genitalia, while 1.3% of
participants ‘never or very rarely’ examine male genitalia. Dermatologists were more
likely to ‘always’ use a chaperone when performing a genital exam on the opposite
gender (female patient 41 [51.25%], 26 male, 15 female dermatologists; male patient
26 [32.5%]; 19 female, 7 male dermatologists), with male dermatologists more likely
to ‘always’ use a chaperone (P \.0001) with cisgender female patients. 47.25% had
an overall positive perception of chaperone use, with 31.3% of physicians ‘very
familiar’ with their clinic/hospital chaperone policy.
Conclusion: Our findings highlight the variability of chaperone use and gender
differences among dermatologists when performing genital examinations.
Commercial Disclosure: None identified.
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27630
Assessing signs and symptoms of hidradenitis suppurativa from
the patient perspective
Afsaneh Alavi, MD, University of Toronto; Iltefat H. Hamzavi, MD,
Henry Ford Hospital; Sarah Baradaran, Janssen Research &
Development, LLC; Susan D. Mathias, MPH, Health Outcomes Solutions; Hilary
H. Colwell, Health Outcomes Solutions; Michael Song, Janssen Research &
Development, LLC; Chenglong Han, Janssen Research & Development, LLC
Background: Qualitative research was conducted to develop a patient reported
outcome (PRO) measure assessing symptoms/signs of hidradenitis suppurativa (HS),
the HS Symptom Diary (HSSD).
Methods: Concept elicitation (CE) and combined CE/cognitive debriefing (CD)
interviews were conducted with adult patients with moderate-to-severe HS from 5
dermatology practices in North America. The CE portion of the interview sought to
fully understand important concepts of HS. Subjects then completed the draft HSSD,
and answered questions to evaluate its content, clarity, and relevance. Revisions
were made iteratively to the HSSD. The study received institutional review board
approval; subjects provided written informed consent.
Results: 36 subjects were interviewed [6 ¼ CE and 30 ¼ CE/CD, 65% female; mean
age ¼ 39]. The most commonly reported lesion locations were armpits (81%), groin
(75%), or under the breasts (31%). Subjects reported pain (100%), drainage (100%),
itching (100%), swelling/ inflammation (94%), odor (86%), tenderness (81%), heat
(64%), and pressure (64%) related to their lesions. The most bothersome symptoms
were pain (94%), drainage (50%), swelling/inflammation (42%), and itching (33%).
Pain was the most difficult symptom to manage (53%). In general, respondents were
able to paraphrase each item and found the content to be clear and relevant. The
final HSSD, developed as a daily diary with a 24-hour recall period, contains 8 items
evaluating severity of each symptom/sign using an 11-point numeric rating scale. A
7-day version was also developed.
Conclusion: Content validity of the HSSD in patients with moderate-to-severe HS has
been demonstrated. Its measurement properties will be assessed using data from
upcoming clinical studies.
Commercial Disclosure: 100% is sponsored by Janssen Research & Development,
LLC.
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